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ABSTRACT The role of major histocompatibility complex
(MHC) class I expression in control of the sensitivity of normal
cells to natural killer (NK) cells was studied by the use of
mutant mice made deficient for expression of P2-microglobulin
(zmm) through homologous recombination in embryonal stem
cells. T-cell blasts from f2m-deficient (382m -/-) mice were
killed by NK cells from mormal mice in vitro, while 12m +/-
blasts were resistant. The 2m defect also affected the NK
effector cell repertoire: NK cells from P2m -/- mice failed to
kill f2m-/- blasts, while they retained the ability to kill the
prototype NK cell target lymphoma YAC-1, although at re-
duced levels. The inability to recognize P2m -/- blasts could
be transrred with P2n-- bone marrow to irradiated
f2m-expressing mice. In contrast, the development of CD8+ T
cells (deficient in 2m -/- mice) was restored in such
chimera. These results indicate that loss of MHC dass I/B2m
expression is sufficient to render normal cells sensitive to NK
cells, and that the same defect in the hemopoietic system of a
mouse renders its NK cells tolerant to P2m-deficient but
otherwise normal cells. In the 2m -- mice, NK cells may
be selected or educated by other bone marrow cells to tolerate
the MHC cass I deficiency. Alternatively, the specificity may
be controlled dicdy by the class I molecules on the NK cells
themselves.
One function of innate immunity may be to detect "missing
self"-i.e., incomplete expression of host major histocom-
patibility complex (MHC) class I products (1, 2). This is
supported by natural killer (NK) cell rejection of tumor and
bone marrow grafts lacking either an MHC class I transgene
(3, 4) or P2-microglobulin (2m; ref. 5), expressed by the
recipients. Reduced MHC class I expression has been asso-
ciated with high sensitivity to NK cells in a number of
different murine and human tumor systems (for reviews, see
refs. 2 and 6), but is loss of self MHC class I expression
sufficient to render normal, nontransformed cells 'directly
sensitive to NK cell lysis? Recognition of this phenotype
would then be one important basis for the surveillance
function of NK cells, regardless of antigens dependent on
transformation or viral infection. If the MHC indeed influ-
ences the sensitivity of normal cells to NK cells, how is the
NK cell repertoire affected by maturation in a class I-defi-
cient environment? These questions were addressed in the
present study by the use of .2m-deficient mice obtained after
homologous recombination in embryonal stem cells. The
previous analysis oftwo such lines of /32m-deficient mice has
yielded important insights into the role of MHC class I
molecules in immune functions (7-10). In particular, the mice
were shown to be devoid of the CD8' T-cell subset in the
periphery (8, 10) and were unable to mount a primary CTL
response against allogeneic cells (10). As (2m is required for
the cell-surface expression of MHC class I heavy chains,
these results show thatMHC class I plays a critical role in the
development of CD8' T cells.
Our experimental approach here was based on the use of
concanavalin A (Con A)-activated blasts from B2m -/- and
(32m +/- mice as targets for NK cells from different hosts.
Since our results indicated that the (32m deficiency affected
not only the sensitivity of normal cells to NK cells but also
the NK cell repertoire at the host-effector cell level, we used
bone marrow chimeric mice to ask how MHC class I expres-
sion in the periphery influenced the development ofNK cells
from (32m-deficient bone marrow. The development ofCD8'
cells under the same conditions was studied for comparison
and control.
MATERIALS AND METHODS
Mice and Cell Lines. Generation of the (32m-defective mice
has been described (7, 8). Briefly, one copy of the P(2m gene
in the embryonal stem cell line E14TG2A [129(129/J)/Ola]
was disrupted by homologous recombination. Cells carrying
the mutated gene were injected into C57BL/6 (B6) blasto-
cysts which, when allowed-to continue development in vivo,
gave rise to chimeric animals. When mated with B6 mice, a
number of these chimeras transmitted the embryonal stem
cell genome to their offspring. Halfofthese had also inherited
the mutated P2m gene. When these F1 32m +/- animals were
mated with one another, expected ratios ofhomozygous Pfm
-/-, p2m + /+, and heterozygous #2m + /- animals were
seen. Such F2 animals were used in some of the experiments
in this paper. Additional (2m -/- and j2m +/- mice were
obtained by crossing F2-generation animals. B6 and 129 mice
were purchased from Alab (Sollentuna, Sweden) and The
Jackson Laboratory, respectively. YAC-1 is a Moloney mu-
rine leukemia virus-induced T-cell lymphoma of the A/Sn
strain, and P815 is a methylcholanthrene-induced mastocy-
toma from the DBA strain.
Antibodies. The following reagents were used in fluores-
cence-activated cell sorter (FACS) analysis and effector cell
depletion; monoclonal antibodies (mAb) against H-2Kb
(AF6-88.5.3), H-2Db (28-14-8S) (American Type Culture Col-
Abbreviations: 2m, 2-microglobulin; MHC, major histocompati-
bility complex; NK, natural killer; Con A, concanavalin A; CTL,
cytotoxic T lymphocytes; mAb, monoclonal antibody; C, comple-
ment.
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lection), CD8 [MAS 111; fluorescein isothiocyanate (FITC)-
conjugated, Sera-Lab, Crawley Down, Sussex, U.K.], and
NK1.1 (PK136; ref. 11); and antiserum agaii*st the ganglio-
side asialo-GM1 (Wako Biochemicals). FITC-conjugated an-
ti-NK1.1 mAb was used for immunofluorescence.
Generation of Con A-Activated T-Cell Blasts. Spleen cells
were depleted from erythrocytes by osmotic lysis and incu-
bated for 48 hr at 5 x 106/ml in RPMI 1640 medium
supplemented with 5% (vol/vol) fetal calf serum and 5 ,ug of
Con A per ml. Before use as targets in a standard 4-hr 51Cr
cytotoxicity assay, dead cells were removed by centrifuga-
tion wifii Lymphoprep (Nycomed, Oslo).
In Vitr Cytotoxicity Assay and Effector-Cell Depletion. NK
effector pells were prepared from erythrocyte-depleted fresh
spleen cells from mice treated with 2 mg of tte interferon
induceF tilorone (Sigma; T-8014) to augment NK cell activity
1-2 days before the assay. Cytotoxic T lymphocytes (CTL)
were generated in a primary (Table 1, expe ments 1 and 2)
or secondary (Table 1, experiment 3; 1 wiedc after immuni-
zation of responder mice with DBA spleen cells) mixed
lymphocyte cultures. Chimeric responder spleeg cells (25 x
106) were mixed with 2000 R-irradiateq -BA stimulator
spleen cells (10 x 106). The CTL assays were made on day
6 with Con A-activated blasts or P815 cells as target cells. To
deplete effector cell subpopulations in vitro, spleen cells were
incubated for 30 min at 4°C either alone or with the first
antibody, washed, and further incubated with a 1:8 dilution
of rabbit complement (C; Pel-Freez Bidloogicals) for 60 min at
37°C. Surviving cells were washed and used directly as
effector cells. To deplete NK cells in vivo, 0.2 ml of ascites
fluid containing anti-NK1.1 mAb or 25 gI of asialo-GM1
antiserum (diluted in phosphate-buffered saline to 0.2 ml) was
inoculated respectively i.p. or i.v. 1 day before the assay.
Immunofluorescence Analysis. Expression of NK1.1 mAb
was analyzed on nylon wool-passaged splenocytes and
expression of H-2Kb, H-2Db, and CD8 was analyzed on
lymph node cells by using a fluorescence-activated cell sorter
(FACS; Becton Dickinson). The cells were incubated for 30
min at 4°C with specific antibody, washed, and, in the case
of H-2 antibodies, incubated with a second fluorescent anti-
body against mouse immupoglobulin (Dakopatts, Hagersten,
Sweden).
Bone Marrow Chimeric Mice. To generate bone marrow
chimeras, B6 recipient mice were irradiated with 900 R and
inoculated i.v. with 20-30 x 106 bone marrow cells. Mice
given P2m -/- and P2m +/- bone marrow cells were treated
with anti-NK1.1 mAb before transplantation. Chimeric mice
were tested after 2 months.
RESULTS
f2m-Deflcient T-Cell Blasts Are Killed by NK Cells in Vitro.
T-cell blasts were prepared by treatment of splenocytes
isolated from f2m -/-, f32m +/-, and control 129 mice with
the T-cell mitogen Con A. T-cell blasts from 129 and 82m
+/- mice were relatively resistant to lysis by fresh spleno-
cytes from B6 or CBA, while blasts from P2m -/- animals
were sensitive (Fig. 1). Killing of the 182m -/- cells was
abrogated when splenocytes from mice treated with either
anti-NK1.1 mAb (11) or antiserum against asialo-GM1 were
used (Fig. 2 A and B). Both of these agents are known to
deplete NK cells in mice after in vivo treatment. This
indicated that, as is the case with a number oftumor cell lines
(2), loss of MHC class I expression renders T-cell blasts
sensitive to lysis by NK cells.
NK Cells from fi2m-Deficient Mice Do Not Kill (32m-
Deficient Con A-Activated Blasts. Previous results have led to
the hypothesis that the NK cell repertoire is calibrated
according to the host MHC class I products so that reactivity
to cells expressing a complete set of self products is avoided
(1, 2). For example, NK cells from H-2Dd transgenic B6 mice
(but not from normal B6 mice) rejected H-2b lymphoma and
bone marrow cells (S, 4). H-2Dd transfectant lymphoma cells
(12) and H-2Dd transgenic bone marrow cells (4) were ac-
cepted in the transgenic host. This hypothesis predicted that
NK cells from 32m -/- mice should tolerate MHC class
I/132m-deficient cells. Spleen cells of 832m -/- mice were
indeed unable to kill f32m -/- blasts in vitro, while those
from f2m +/- mice gave the same levels of killing as cells
from B6 mice (Fig. 3). The phenotype ofthe killer cells in 82m
+/- mice against f32m -/- Con A-activated blasts was
CD8- and asialo-GM1+-i.e., that of typical NK cells (Fig.
2C). The inability of P2m -/- mice to kill and reject ,82m
-/- cells was not due to total lack of NK activity; their
Table 1. NK cell activity, allospecific CTL response, and cell surface phenotype of lymphoid cells in bone marrow chimeric mice
CTL lysis
NK cell lysist Cell-surface phenotypet P815 (H-2d) targetsO
Mice* j32m -/- blasts YAC-1 cells H-2Kb H-2Db CD8 DBA blasts§ C C/anti-CD8 C/anti-H-2Db
Exp. 1 and 2
2m -/-0, 0, 0 NT 0 0 2 NT
1, 2, 2 NT NT NT NT 0, 0
12m-/-- B6 2, 0, 0 30, 20, 15 13 8 15 NT
4, 0, 0 23, 15, 11 9 7 17 NT
3, 0, 0 20, 16, 11 NT NT NT 24, 2
P2m +/- - B6 27, 19, 15 42, 13, 18 97 88 16 NT
B6-B6 33, 23, 15 58, 38, 25 95 98 35 NT
20, 12, 8 37, 24, 16 NT NT NT 17, 15
Exp. 3
B6 B6 27, 15, 8 2, 2, 1 5, 0, 3
129 B6 37, 11, 2 6, 5, 0 1, 1, 5
pm -/-- B6 43, 26, 10 14, 0, 0 33, 18, 3
NT, not tested.
*Normal P2m -/- mice were compared with chimeric B6 mice given either 2m -/-, 2m +/-, or B6 bone marrow. Individually tested mice
from three experiments.
tEffector-to-target ratios were 200:1, 100:1, and 50:1.
tPercent positive cells.
§Effector-to-target ratios were 50:1 and 10:1. The ability to generate anti P815 CTL was confirmed with additional (32m -/- - B6 chimeras
stimulated in mixed lymphocyte culture with B1O.A(SR) spleen cells (data not shown).
lEffector-to-target ratios were 50:1, 10:1, and 2:1.
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FIG. 1. Sensitivity of Con A-activated blasts to NK cells in vitro. (A) Lysis of blasts from 2m -/- mice (o) and from 129 mice (M) by CBA
spleen cells. (B) Same as in A but with spleen cells from B6 mice. (C) Lysis of blasts from 2m -/- (o), 129 (e), and f32m +/- heterozygotes
(o) by spleen cells from B6 mice. E:T ratio, effector-to-target cell ratio.
spleen cells were able to kill the standard target YAC-1 (Fig.
3). This killing and the killing of YAC-1 by cells of im +/-
mice were mediated by asialo-GM1+ cells (Fig. 2 D and E).
In most experiments, the YAC-1 lysis by f2m-deficient NK
cells was lower when compared with +/- NK cells. In a
comparison of data from four consecutive experiments (Ta-
ble 2), the average lysis with effector cells from eight indi-
yidually tested (32m -/- mice was reduced 50%o in terms of
lysis and approximately 75% in terms ofeffector cell dilutions
compared with effector cells from P2m +/- mice. On the
other hand, there was a considerable variation in lysis of
YAC-1 cells with efficient killing also by effector cells from
f32m -/- mice in some experiments, whereas they always
faied to kill rim -/- Con A-treated blasts. For example, in
the second experiment in Fig. 3 (Fig. 3 Right), f2m -/-
effector cells killed YAC-1 more efficiently than h2m +/-
cells and yet failed to kill P2m /- Con A-treated blasts. The
overall pattern suggests that the two activities are regulated
i' part by different mechanisms. Therefore, the inability to
killI32m -/- Con A-activated blasts is not simply due to





























(see Discussion). This explanation is in line with the obser-
vation that the number of NK1.1' cells in the spleens off2m
-/-, P2m +/-, and p2m +/+ mice was similar (10%, 13%,
and 8% NK1.1+ cells, respectively, in erythrocyte-depleted,
nylon wool-passaged spleen cells stained with a FITC-
conjugated anti-NK1.1 mAb; after correction for cell yields,
each of the genotypes were found to have 2.5-4% NK1.1'
cells in the spleen).
Inability To Kill (2m-Deflcient Con A-Activated Blasts Is
Determined by the Bone Marrow. We used normal mice
reconstituted with (32m-deficient bone marrow (after anti-
NK1.1 mAb conditioning of the host) to ask if a peripheral
expression of MHC class I would break the "tolerance" of
NK cells maturing from the (32m-deficient bone marrow. We
found that f32m -/- to B6 chimeras showed the same
selective defect in the NK repertoire as 832m -/- mice
(killing of YAC-1 cells but not f32m -/- blasts; Table 1). In
contrast, the deficiency in CD8' T-cells of P2m -/- mice
was restored when their marrow-derived precursors matured
in a 32m-expressing environment. The chimeras developed a





















FIG. 2. Lysis ofP2m -/- blasts is mediated by NK cells. (A) Splenocytes from two individually tested nontreated (K) and two individually
tested anti-NK1.1-treated B6 mice (*) as effector cells. (B) Same as in A but with splenocytes from two pooled nontreated (<) and two pooled
,anti-asialo-GM1-treated (*) CBA mice as effector cells. (C) Cell-surface phenotype of P2m +/- effector cells against (32m -/- Con A-treated
blasts. Spleen cells were treated with anti CD8 + C (A), anti-asialo-Gml+ C (*), or with C alone (0) before the test. Lysis of YAC-1 cells was
mediated by asialo-GM1+ cells in both k82m -/- (D) and ,32m +/- (E) mice. Spleen cells were treated with complement alone (K) or with
anti-asialo-GM1 + C (*). The donor of effector spleen cells is indicated above each figure. E:T ratio, effector-to-target cell ratio.
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FIG. 3. p2m -/- NK cells do not kill (32m -/- blasts. (A) Lysis of blasts from ,82m -/- (o), 129 (e), and P2m +/- (n) mice by spleen
cells from h2m +/- (Left) and P2m -/- (Right) mice. Lysis ofYAC-1 in the same experiment is indicated (A). (B) Same as inA but from another
experiment. The values represent in each case individually tested mice from representative experiments. Killing of 12m -/- blasts typically
reached 15-25% lysis in a 4-hr cytotoxicity assay, although higher levels were observed occasionally with very efficient effector cells (B). Such
effector cells were also able to kill 129 blasts to a certain extent, even when the relative difference between these and the more sensitive P2m
-/- blasts was maintained (B). E:T ratio, effector-to-target cell ratio.
-/- mice (8, 10) and they were able to mount a cytotoxic
mixed lymphocyte culture response to allogeneic spleen cell
and tumor targets (Table 1). This response was mediated by
CD8+, H-2Db- effector cells (Table 1), indicating that mat-
uration in f32m +/- mice allowed the differentiation ofCD8+
CTL from P2m -/- bone marrow.
DISCUSSION
Increased sensitivity to NK cells in vitro and rejection in vivo
have been observed for several mutant tumor cell lines
lacking MHC class I expression, but there are also examples
of tumor systems where no such relation exists (for review,
see refs. 2 and 6). It has not been clear whether the latter
tumor lines are more representative of normal cells in this
regard, implying that other changes besides (or without) loss
of class I expression are required to make normal cells
sensitive to NK cells. The present results answer this
question, and we conclude (i) that homozygous loss of the
f32m gene, coding for the light chain of the class I molecule,
is sufficient to make at least some normal cells susceptible to
recognition by NK cells; (it) that NK cells of f32m -/- mice
have lost the ability to kill normal P2m-deficient targets,
although NK cell recognition of the standard target YAC-1
persists; and (iii) that P2m/MHC class I deficiency in the
hematopoietic system (j2m -/- to B6 chimeras) is sufficient
to calibrate the NK cells to tolerate normal p2m -/- cells,
whereas selection ofCD8' T cells, also deficient in «3m -/-
mice, can occur under conditions where class I expression is
present only in nonhematopoietic cells. Similar to the find-
Table 2. Killing of YAC-1 by effector cells from P2m -/- and
32m +/- mice
NK cell lysis of YAC-1*
Mice 100:1 50:1 25:1
2m -- 20 ± 14.8 17 ± 12.1 10 ± 11
,P2M +/- 37 ± 12 29 ± 9.1 21 ± 7.6
*Mean lysis values of YAC-1 from four consecutive experiments
with effector cells from eight (32m -/- and eight 832m +/- mice
tested individually. By using a two-tailed nonpaired t test, the
differences between the two genotypes were found to be statistically
significant in the two highest effector-to-target ratios (P < 0.05).
Means ± SD are shown.
ings reported by Bix et al. (5) during the progress of this
study, we have found that bone marrow from our indepen-
dently derived line of h32m -/- mice was rejected by NK
cells from normal mice (C.O., unpublished data). This finding
and the observation that P32m -/- mice were unable to reject
32m-deficient bone marrow (ref. 5; C.O., unpublished data)
can be explained on the basis of the in vitro results in this
paper: P2m -/- bone marrow cells are rejected because they
are directly sensitive to NK cells in nonmutant mice. How-
ever, tolerance to autologous cells is maintained by NK cells
in the /2m-deficient mice, and the ,2m -/- marrow grafts
are thus accepted.
There are two possibilities for how NK cells may detect
"missing self." The "effector inhibition" model postulates a
MHC class I-dependent negative signal to NK cells (2). The
alternative "target interference" model assumes a MHC
class I-dependent masking or modulation of a triggering
molecule at the target cell level, as originally proposed by
Storkus and Dawson (for review, see ref. 6). In context ofthe
latter model, the killing of f82m -/- Con A-activated blasts
may be triggered by molecules revealed only after phenotypic
loss of dominant MHC class I products. If different class I
alleles vary in their efficiency to interfere with target mole-
cules, the latter will behave genetically as recessive MHC-
linked antigens, whether or not they are encoded within the
MHC proper. This pattern of inheritance is the one postu-
lated for Hh antigens, proposed to be target molecules in NK
cell-mediated rejection of allogeneic and parental bone mar-
row grafts (13, 14). Therefore, our present results, interpreted
within a target interference model, may be reconciled with
the previous genetic studies ofbone marrow graft rejection in
the mouse (13, 14) and more recent reports of allospecific NK
cell responses in humans (15). These have shown that target
sensitivity of T-cell blasts to certain NK cell clones may be
under negative control of dominant, HLA-linked genes (16).
It cannot be excluded that class I molecules are responsible
for this down-regulation (16).
The allospecific reactivity by human NK clones is regu-
lated independently of the tumor target killing (15). This
pattern is reminiscent of the selective defect in natural killing
of normal cells (as opposed to YAC-1 lymphoma cells)
observed in the present study. There are at least two hy-
potheses to explain this "hole" in the NK repertoire against
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subset of NK1.1' cells in the 32m -/- mice and (it) down-
regulation of a specific receptor present on all NK1.1' cells.
The equal number of NK1.1' cells in nonmutant and mutant
mice speaks against deletion of a major subset ofNK cells in
(32m -/- mice, although the disappearance of a small fraction
cannot be excluded. Further studies require methods to dis-
tinguish different NK1.1' cells, for example in the CD3' (17,
18), CD3-/5E6+ (19), and CD3-/5E6- subsets. The CD3-/
5E6+ population should be particularly interesting, since it
contains all of the NK cell reactivity of B6 mice against
mismatched bone marrow grafts, at least of the H-2d type (19).
The idea of down-regulation of a specific receptor type (re-
sponsible for killing of Con A-activated blasts and bone
marrow) on all NK cells must be kept open. It can also explain
the reduced but not totally abolished killing of YAC-1 (Table
2). According to a "multiple choice" model forNK specificity
(20), a single NK cell can operate with different receptor-
target interactions in different situations. Thus, YAC-1 may be
killed partly by an interaction dependent on its low class I
expression (21) and partly by an interaction with tumor-
associated structures. Only the former would be affected by
the f2m defect of the effector cell donor, thus explaining the
remaining killer potential against YAC-1 targets. Whatever
mechanism is responsible, it appears to be sufficient with a
f32m defect ofbone marrow cells to prevent development ofthe
ability to kill (32m -/- blasts in the NK repertoire. The defect
may have consequences in the NK cells themselves (e.g.,
receptors may depend on MHC class I/p32m for transport to
the cell surface of effector cells) or in other bone marrow-
derived cells whose class I molecules normally select certain
NK subsets or NK receptors. To explore these possibilities
further, 02m must be reexpressed selectively in different types
of bone marrow-derived cells. Previous work with chimeras
has demonstrated that non-MHC genes in the bone marrow
control the general levels ofNK cell activity (22).
The present results with bone marrow chimeras also dem-
onstrate that the defect in the NK cell repertoire in j32m -/-
mice is notjust secondary to the CD8+ T-cell defect, since the
latter but not the former was restored in f32m -/- to B6
chimeras. The development of CD8+ T cells in these chime-
ras is hardly surprising, since thymic epithelium is considered
as the crucial site of expression for MHC class I molecules in
positive selection ofCD8+ T cells (23). Further studies ofNK
cells in the 82m-deficient mice may lead to the molecular
characterization of NK subsets and effector-target interac-
tions as well as the process by which the NK cell repertoire
is shaped by the class I phenotype of the bone marrow.
Note Added in Proof. After the submission of this report, similar data
showing that,82m -/- Con A-activated blasts are recognized by NK
cells from normal but not from 82 -/- mice have been reported by
Liao et al., using an independently derived f82m-deficient mouse
strain (24).
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